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ABSTRACT
The majority of lung cancer deaths are caused by metastatic disease. MicroRNAs 
(miRNAs) are posttranscriptional regulators of gene expression and miRNA 
dysregulation can contribute to metastatic progression. Here, small RNA sequencing 
was used to profile the miRNA and piwi-interacting RNA (piRNA) transcriptomes in 
relation to lung cancer metastasis. RNA-seq was performed using RNA extracted 
from formalin-fixed paraffin embedded (FFPE) lung adenocarcinomas (LAC) and brain 
metastases from 8 patients, and LACs from 8 patients without detectable metastatic 
disease.  Impact on miRNA and piRNA transcriptomes was subtle with 9 miRNAs 
and 8 piRNAs demonstrating differential expression between metastasizing and 
non-metastasizing LACs. For piRNAs, decreased expression of piR-57125 was the 
most significantly associated with distant metastasis. Validation by RT-qPCR in a LAC 
cohort comprising 52 patients confirmed that decreased expression of miR-30a-3p  
and increased expression of miR-210-3p were significantly associated with the 
presence of distant metastases. miR-210-3p tumor cell specificity was evaluated by 
in situ hybridization and its biomarker potential was confirmed by ROC curve analysis 
(AUC = 0.839). Lastly, agreement between miRNA-seq and RT-qPCR for FFPE-derived 
RNA was evaluated and a high level of concordance was determined. In conclusion, 
this study has identified and validated metastasis-related miRNAs in LAC.  
INTRODUCTION
Lung cancer has the highest mortality rate of all human 
cancers and is every year liable for approximately 1.5 million 
deaths worldwide [1, 2]. Lung cancer is a heterogeneous 
disease with two primary subtypes, small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC).  About 85% 
of all newly diagnosed lung cancers are NSCLCs and they are 
further subdivided into adenocarcinomas, squamous cell and 
large cell carcinomas. Lung adenocarcinoma (LAC) is the most 
common NSCLC subtype and accounts for approximately 
40% of all lung cancer cases [3]. The overall 5-year survival 
rate of lung cancer is 15%, but it varies extensively depending 
on how advanced the cancer is at the time of diagnosis [4, 5]. 
Patients diagnosed with localized lung tumors currently have 
a 50% chance of surviving at least 5 years following their 
diagnosis, but this number drops to 25% if the disease has 
spread to regional lymph nodes and to merely 5% for patients 
diagnosed with distant metastatic lesions [3]. It is therefore not 
the primary lung tumor itself, but rather the metastatic spread 
of the disease that can be held accountable for lung cancers 
continuously high mortality rate. This is the current situation 
for most human malignancies as 90% of all cancer deaths 
are caused by metastatic disease [6, 7]. It is therefore critical 
to elucidate the molecular mechanisms that characterize the 
metastatic process.  
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MicroRNAs (miRNAs) are a class of small non-
coding RNAs (~22nt in length) that regulate gene 
expression through repression of target messenger RNA 
(mRNA) expression [8]. More than 50% of all protein-
coding genes are currently believed to be under strict 
microRNA regulation and alterations in miRNA expression 
can therefore have severe consequences and contribute to 
the pathogenesis of human malignancies [8–11]. 
Aberrant miRNA expression has also been 
implicated in the development and metastatic progression 
of lung cancer [12–14]. In 2004, Takamizawa et al. 
published one of the first reports of miRNA dysregulation 
in lung cancer, demonstrating that reduced expression 
of let-7 was associated with decreased postoperative 
survival. The role of let-7 in lung cancer has since been 
extensively investigated and it has been shown to exercise 
its tumor suppressive function by targeting multiple 
critical oncogenes, including MYC and RAS [15–17]. 
Numerous other oncomiRs and tumor suppressor miRNAs 
have been identified in NSCLC and in 2013, Vosa et al. 
published a comprehensive meta-analysis identifying a 
miRNA meta-signature of seven upregulated (miR-21, 
miR-210, miR-182, miR-31, miR-200b, miR-205, miR-183) 
and eight downregulated (miR-126-3p, miR-126-5p, 
miR-30a, miR-30d, miR-486-5p, miR-451a, miR-143, 
miR-145) miRNAs in NSCLC [18–20]. Furthermore, 
increased expression of miR-135b was recently identified 
as an independent predictor of poor overall survival in 
NSCLC and shown to promote lung cancer metastasis 
in vitro and in vivo by targeting multiple genes in the 
Hippo pathway, including LATS2, β-TrCP and NDR [21]. 
Similarly, miR-193a has been identified as an inhibitor 
of NSCLC metastasis by downregulating the ERBB4/
PIK3R3/mTOR/S6K2 signaling pathway and miR-29b 
has been shown to suppress proliferation, migration and 
invasion abilities of lung cancer cells by targeting PTEN 
and MMP2, as well as being significantly associated with 
lymph node metastasis in NSCLC [22, 23]. 
P-element-induced wimpy testis (PIWI)-interacting 
RNAs (piRNAs) are another type of small non-coding 
RNAs (26-33nt) and with approximately 20.000 genes 
in the human genome, piRNAs parallel protein coding 
genes and vastly exceed miRNAs in abundance (~2.000 
genes) [24, 25]. The role of piRNA in human disease has 
not been studied as extensively as miRNA, but they have 
recently been recognized as co-players in the development 
and progression of human cancers, including lung cancer 
[26, 27]. In fact, piR-55490 was recently reported to be 
downregulated in lung cancer patient specimens and to 
be significantly associated with poor overall survival. 
Moreover, piR-55490 was shown to function as a potent 
tumor suppressor by inducing degradation of mTOR 
mRNA in a miRNA-like manner and thereby suppressing 
the activation of the Akt/mTOR pathway, leading to 
inhibition of lung cancer cell proliferation [28].  
RT-qPCR and hybridization-based microarray 
platforms have previously been the methods of choice 
to study aberrant miRNA expression in lung cancer, but 
these technologies will only allow expression analyses 
of a limited number of known miRNAs. With the advent 
of next-generation sequencing (NGS), a powerful new 
tool for global miRNA expression analysis has emerged 
(miRNA-seq). A couple of studies have successfully 
employed miRNA-seq to profile differences in miRNA 
expression between primary lung tumors and tumor-
adjacent normal lung, as well as to study the expression 
of circulating miRNA in serum and peripheral blood 
from NSCLC [29–32]. However, miRNA-seq has, to the 
best of our knowledge, not previously been employed 
to study the miRNA transcriptome in relation to lung 
cancer metastasis. In this study, we aimed to characterize 
the miRNA transcriptome in non-metastasizing and 
metastasizing LACs with paired brain metastases using 
miRNA-Seq, as well as to validate our findings in two 
LAC metastasis cohorts by RT-qPCR. 
RESULTS
miRNA-seq
In order to characterize the miRNA transcriptome 
in relation to lung cancer metastasis, we selected primary 
LACs from 8 patients without detectable distant metastatic 
lesions and a minimum of 5 years of recurrence-free 
survival, as well as primary LACs and paired brain 
metastases from 8 patients that suffered from distant 
metastatic disease at the time of diagnosis to undergo 
miRNA-seq analysis. The 16 patients were paired on 
gender, age, smoking status, T-stage and the relative 
proportion of tumor cells in the surgical resections. The 
clinical characteristics of the selected patients are shown 
in Supplementary Table 1. The RNA integrity in the 24 
selected patient samples (8 LACs without metastases, 
8 LACs with metastases and 8 paired brain metastases) 
was assessed prior to preparing the small RNA libraries 
(Supplementary Figure 1A). All samples demonstrated 
a high degree of RNA degradation as observed by the 
predominant presence of small RNA fragments (< 500 bp) 
and the determined RIN values, which ranged from 2.20 
to 2.50. Such low RNA quality is, however, what can be 
expected for RNA extracted from formalin-fixed, paraffin 
embedded (FFPE) archive material. Successful miRNA-
seq of RNA extracted from FFPE material has previously 
been reported and we therefore proceeded with the library 
preparation despite the high degree of RNA degradation 
[33–35]. The stability of small RNAs such as miRNAs 
and piRNAs did allow us to successfully prepare the 
small RNA libraries with a clear enrichment of fragments 
with the expected size of approx. 145 bp (Supplementary 
Figure 1B). The small RNA libraries were subsequently 
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sequenced and the average distribution of detected RNA 
species is shown in Figure 1. Degradation of larger RNA 
species, such as ribosomal RNA (rRNA) and messenger 
RNAs (mRNAs), did influence the output from the small 
RNA sequencing as 32.7% and 12.5% of sequence reads 
were determined to originate from rRNA and mRNA, 
respectively. However, 14.4% and 10.9% of sequencing 
reads were still detected from miRNAs and piRNAs, 
respectively. 
Characterization of the miRNA transcriptome in 
metastasizing and non-metastasizing LAC 
A full list of all miRNAs detected by miRNA-seq 
sorted according to total mean expression in all samples 
is provided in Supplementary Table 2. A total of 189 
miRNAs demonstrated a mean expression level of more 
than 100 counts per million (CPM) miRNA reads and 
the expression levels of these miRNAs were compared 
between the LACs without distant metastases and LACs 
with distant metastases. The miRNAs were sorted 
according to the most significant change in expression 
between the two groups and the results are shown in 
Supplementary Table 3 and visualized as a heatmap in 
Supplementary Figure 2. Due to the size similarity between 
miRNA and piRNA, we also obtained full expression 
profile for piRNA. A complete list of all detected piRNA 
sorted according to total mean expression in all samples is 
shown in Supplementary Table 4. 120 piRNAs showed a 
mean expression level of more than 100 counts per million 
piRNA counts (CPM) and their expression was compared 
between the LACs with and without distant metastases. 
The piRNAs were then sorted by the most significant 
change in expression between the two groups and the 
results are shown in Supplementary Table 5 and depicted 
as a heatmap in Supplementary Figure 3. 
Only subtle differences in expression were detected 
between the metastasizing and non-metastasizing LACs 
for both miRNAs and piRNA (Supplementary Figures 2 
and 3). Nine miRNAs demonstrated a significant change 
in expression between the two groups: miR-101-3p 
(p = 0.0020), miR-210-3p (p = 0.0051), miR-15a-5p 
(p = 0.0195), miR-130a-3p (p = 0.0227), let-7e-5p 
(p = 0.0235), miR-16-5p (p = 0.0246), miR-342-3p 
(p = 0.0262), miR-769-5p (p = 0.0272) and miR-361-
5p (p = 0.0273) (Figure 2A). Similarly, a significant 
change in expression was detected for 8 piRNA: 
piR-57125 (p = 0.0068), piR-36196 (p = 0.0172), 
piR-31701 (p = 0.0313), piR-41435 (p = 0.0325), piR-
31935 (p = 0.0326), piR-46895 (p = 0.0396), piR-31052 
(p = 0.0477) and piR-61651 (p = 0.0494) (Figure 2B). 
Similar changes in expression were observed in the paired 
brain metastases for the majority of the miRNAs and 
piRNA, but due to the considerable difference in average 
tumor cell content between the primary tumors and brain 
metastases, the expression results could not be compared 
directly (Supplementary Table 1). Based upon the miRNA-
seq analysis, we selected 10 miRNAs that showed a 
significant or near significant difference in expression 
between the metastasizing and non-metastasizing LACs to 
undergo validation by RT-qPCR. The 10 selected miRNAs, 
including mean CPM, standard error of the mean (SEM) 
and p-value determining the significance of the difference 
in expression are shown in Table 1.
Figure 1: RNA species detected by miRNA-seq. Pie chart demonstrating the mean distribution of different RNA species detected 
by miRNA-seq in all sequenced samples. 
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High concordance between miRNA-Seq and  
RT-qPCR in FFPE material
This study was conducted using highly 
degraded RNA extracted from FFPE archive material 
(Supplementary Figure 1), and we therefore performed 
an initial RT-qPCR validation to confirm our miRNA-seq 
results. The expression level of the 10 selected miRNAs 
was determined by RT-qPCR in the same 24 patient 
samples and the miRNA-seq and RT-qPCR expression 
values were then normalized to enable direct comparison. 
For each miRNA in each of the 24 samples, log2 converted 
normalized expression values were generated for the two 
methods separately: For RT-qPCR, normalized expression 
values were generated by dividing the RQ of a given 
miRNA in each sample to the mean RQ of said miRNA 
in all 24 samples and subsequently log2 converted. For 
miRNA-seq, normalized expression values were generated 
by dividing the CPM of a given miRNA in each sample 
to the mean CPM of said miRNA in all 24 samples and 
subsequently log2 converted. The log2 (normalized 
expression) values obtained by RT-qPCR were then plotted 
against those obtained by miRNA-seq (Figure 3). The 
level of agreement between the two methodologies was 
determined by correlation analysis and linear regression. 
The correlation analysis yielded a Pearson correlation 
coefficient, r = 0.7202 and a p-value < 0.0001 thus showing 
a strong correlation between the results obtained by the 
two methods. Similarly, the linear regression determined 
the Line of Best Fit as Y = 0.8893X – 0.1257, which 
approximates the ideal line, Y = X.  We can therefore 
conclude that there is a high concordance between the 
results obtained by miRNA-seq and RT-qPCR despite the 
high level of RNA degradation present in FFPE material. 
Table 1: miRNA-seq results for miRNAs selected for RT-qPCR validation
ID
LAC w/o metastases LAC w/ metastases Brain metastases LAC w/o metastases vs. LAC w/ metastases
Mean
(CPM) SEM
Mean
(CPM) SEM
Mean
(CPM) SEM P
miR-101-3p 2612 221 1579 159 1021 223 0.0020
miR-210-3p 689 116 1128 63 1704 294 0.0051
miR-15a-5p 1138 91 847 62 1214 151 0.0195
miR-130a-3p 1992 245 1309 107 1345 372 0.0227
miR-16-5p 16161 913 12909 914 19478 1874 0.0246
miR-342-3p 1100 75 806 92 472 71 0.0262
miR-361-5p 380 29 279 29 377 53 0.0273
miR-30a-3p 1245 298 576 120 371 68 0.0559
miR-10b-5p 10195 1826 24564 6965 15307 4573 0.0658
miR-100-5p 11291 3983 3342 262 3090 907 0.0664
Figure 2: Differentially expressed miRNAs and piRNAs determined by miRNA-seq. The miRNA and piRNA expression 
levels determined by miRNA-seq were compared between the primary tumor groups “LAC w/ metastases” and “LAC w/o metastases” 
using a student’s t-test with two-tailed p-values ≤ 0.05 considered statistically significant. The miRNAs and piRNAs that exhibited a 
significant change in expression between the two primary tumor groups are shown in (A) for miRNAs and in (B) for piRNAs. The results 
are shown as bar graphs representing the mean expression in each groups (counts per million miRNA/piRNA counts) with error bars 
indicating the standard error of the mean (SEM). 
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Validation of differentially expressed miRNAs
Following the initial validation, we then determined 
the expression of the 10 selected miRNAs by RT-qPCR 
in the full LAC cohorts comprising LACs from 26 
distant metastases-free patients and LACs from 26 
patients diagnosed with distant metastases, as well as in 
24 paired metastases (20 brain and 4 adrenal gland) and 
10 tumor-adjacent normal lung samples. The clinical 
characteristics of the patients included in the study are 
listed in Supplementary Table 6. All miRNAs selected 
for validation, except miR-361-5p and miR-100-5p, 
showed a significant change in expression between 
tumor-adjacent normal lung and LAC. Two miRNAs 
(miR-210-3p and miR-15a-5p) were significantly 
upregulated and 6 miRNAs (miR-101-3p, miR-130a-3p, 
miR-16-5p, miR-342-3p, miR-30a-3p and miR-10b-5p) 
were downregulated in the tumor tissue compared to the 
normal counterpart (Table 2 and Figure 4). A statistically 
significant change in expression between metastasizing 
and non-metastasizing LACs was confirmed for three 
miRNAs; miR-210-3p, miR-30a-3 and miR-16-5p, 
with similar or more pronounced changes in expression 
levels observed in the paired distant metastases. Next, 
we analyzed publicly available microRNA expression 
datasets through The Cancer Genome Atlas (TGCA) 
database (https://gdc-portal.nci.nih.gov/). Expression 
values were collected for all miRNAs that demonstrated a 
significant change in expression between tumor-adjacent 
normal lung and tumor tissue, or between metastasizing 
and non-metastasizing LACs in our LAC cohorts. We 
first analyzed the expression levels in 46 LAC patients 
with paired tumor-adjacent normal lung and primary 
tumor samples available, validating that miR-210-3p is 
significantly upregulated, whereas miR-101-3p and miR-
30a-3p are significantly downregulated in LAC compared 
to normal lung (Supplementary Figure 4). No difference 
in expression was detected for miR-15a-5p, miR-130a-3p, 
miR-16-5p, miR-342-3p and miR-10b-5p in the TCGA 
samples. Next, we compared the expression levels of 
the three miRNAs that exhibited differential expression 
in our metastasizing and non-metastasizing LACs in 
the TCGA samples with and without distant metastases 
(M1, n = 23 vs. M0, n = 346), TCGA samples with and 
without lymph node metastases (N1 or N2, n = 123 vs. 
N0, n = 219) and TCGA samples from patients with 
and without recurrent disease (YES, n = 123 vs. NO, 
n = 219). For miR-210-3p, we did not find a significant 
association between the expression levels and the included 
clinical parameters, but a clear tendency towards higher 
expression in the metastasizing vs. non-metastasizing 
LACs was observed (mean miRNA expression: 
M1 = 1629 ± 385 CPM (n = 23) vs. M0 = 1231 ± 68.68 CPM 
(n = 346)) (Supplementary Figure 5A). For miR-30a-3p, 
Figure 3: The level of agreement between miRNA-seq and RT-qPCR. The level of agreement between the miRNA-seq and RT-
qPCR expression results was assessed by plotting the log2(normalized expression) values obtained by RT-qPCR for each miRNA vs. those 
obtained by miRNA-seq for all of the 24 patient samples that were included in the miRNA-seq analysis. The level of agreement between 
the two methodologies was determined by linear regression and correlation analysis. The resulting equation for the Line of Best Fit, as well 
as the Pearson’s correlation coefficient, r, and corresponding p-value are shown. 
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we detected a borderline significant association between 
low expression levels and the presence of lymph 
node metastases (p = 0.062) and disease recurrence 
(p = 0.065) (Supplementary Figure 5B). No association 
between miR-16-5p expression levels and the included 
clinical parameters was observed in the TCGA samples 
(Supplementary Figure 5C). In combination, these results 
strongly suggest that upregulation of miR-210-3p and 
downregulation of miR-30a plays an important role in the 
development and metastatic progression of LAC.
Increased miR-210 expression is associated with 
the presence of distant metastases in LAC
miR-210-3p demonstrated the most significant 
change in expression between metastasizing and non-
metastasizing LACs and we therefore chose this miRNA 
for further characterization. miR-210-3p was significantly 
upregulated in both the non-metastasizing (p = 0.0107) 
and metastasizing LACs (p = 0.0005) as compared 
to the tumor adjacent normal lungs (Figure 5A). The 
expression of miR-210-3p was furthermore significantly 
higher in the metastasizing tumors compared to the non-
metastasizing tumors (p = 0.0002) and similarly increased 
levels of expression were detected in the paired distant 
metastases. The RNA used in this study was extracted 
from whole sections of FFPE surgical resections, which 
contain contaminating normal lung cells (Average 
proportion of tumor cells in primary LACs = 33.2%). In 
order to determine if the increased expression of miR-
210-3p was specific for the tumor cells in the sections, 
we investigated miR-210-3p expression by in situ 
hybridization in 3 tumor-adjacent normal lung samples, 3 
LACs without metastases, 3 LAC with metastases and in 
3 paired brain metastases. The areas of high miR-210-3p 
expression (dark purple) co-localize clearly with the tumor 
tissue (Figure 5B). We can therefore conclude that the 
observed increase in miR-210 expression is specific for 
the tumor cells in the sections. The correlation between 
miR-210-3p expression and the clinical characteristics 
of the patients included in this study, such as gender, 
age, smoking status, tumor size (T-stage), presence of 
regional lymph node metastases (N-stage) and presence of 
distant metastases (M-Stage) was investigated (Table 3). 
M-stage (p = 0.0002) was the only clinical parameter to 
show a significant correlation and increased miR-210-3p 
expression is thus specifically associated to the presence 
of distant metastases in LAC. The variation in miR-210-
3p expression in the metastasizing and non-metastasizing 
LACs is shown in Figure 5C. In order to determine if 
miR-210-3p expression holds potential as a diagnostic 
biomarker for distant metastasis in LAC, we performed a 
Receiver Operating Characteristic (ROC) curve analysis. 
It showed an area under the ROC curve (AUC) of 0.839 
(p < 0.0001), which confirmed the high potential of miR-
210-3p expression as a biomarker for formation of distant 
metastases in LAC (Figure 5D).  
Increased miR-210 expression as a consequence 
of promoter hypomethylation
The miR-210 gene is located in an intron of the 
miR-210 host gene (MIR210HG), which coincides with a 
CpG island (CGI). Hypoxia-induced increased expression 
of miR-210 has previously been attributed to promoter 
hypomethylation, and we therefore hypothesized that 
the increased expression observed in the metastasizing 
tumors could be a consequence of a decrease in 
promoter methylation [36]. We therefore investigated the 
methylation status of three different regions of the CGI 
using Methylation-Sensitive High Resolution Melting 
(MS-HRM) analysis. A schematic representation of the 
miR-210’s genomic context is shown in Figure 6A with 
the location of the three MS-HRM assays targeting 
Table 2: miRNAs demonstrating differential expression
ID LAC vs. Normal lung LAC w/ metastases vs. LAC w/o metastases
Change in expression P Change in expression P
miR-101-3p Down 0.001 - -
miR-210-3p Up 0.006 Up 0.0002
miR-15a-5p Up 0.006 - -
miR-130a-3p Down 0.0001 - -
miR-16-5p Down 0.040 Down 0.022
miR-342-3p Down < 0.0001 - -
miR-361-5p - - - -
miR-30a-3p Down 0.153 Down 0.018
miR-10b-5p Down 0.033 - -
miR-100-5p - - - -
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Region 1, 2 and 3, indicated in black. The three regions 
were chosen based on their likelihood of being of 
transcriptional relevance for miR-210/MIR210HG when 
inspecting of the UCSC Genome Browser (Human Feb. 
2009 GRCh37/hg19 Assembly). Regions with a high 
density of transcription factor binding sites, high DNAase 
hypersensitivity and H3K27Ac marks were prioritized 
[37]. The results of the methylation assessment are shown 
in Supplementary Table 7 and visualized as stacked bar 
percentage plots in Figure 6B for Region 1, Figure 6C for 
Region 2 and in Figure 6D for Region 3. Representative 
normalized melting profiles are shown for Region 1 in 
Figure 6E–6G. No significant difference in methylation 
was detected between any of the sample groups and 
largely all samples were unmethylated at all three regions. 
For Region 1, 100% (101/101) of the tested samples were 
unmethylated. For Region 2, 100% (25/25) of the tumor-
adjacent normal lung samples and 100% (26/26) LACs 
without metastases were unmethylated, whereas a non-
significant increase in methylation was detected in 7.7% 
(2/26) of the LACs with metastases and in 8.8% (2/23) of 
the distant metastases. Similar results were obtained for 
Region 3, as 100% (26/26) of the tumor-adjacent normal 
lung samples and 100% (26/26) of the LACs without 
metastases were unmethylated, whereas 3.9% (1/26) of 
the LACs with metastases and 4.4% (1/23) of the distant 
metastases showed an increase in methylation. We can 
therefore conclude that the observed increase in miR-
Figure 4: Validation of differentially expressed miRNAs. The relative quantities (RQ) of the 10 miRNAs that were selected for 
validation were determined in 26 non-metastasizing (LAC w/o M) and 26 metastasizing LACs (LAC w/ M), as well as in 24 paired distant 
metastases (20 brain and 4 adrenal gland) (M), and 10 tumor-adjacent normal lungs (NL) using RT-qPCR. The “LAC” group represents 
the mean expression level in the non-metastasizing and metastasizing LACs combined. The results are shown as bar graphs representing 
the mean expression level in each group with error bars indicating the standard errors of the mean (SEM) for (A) hsa-miR-101-3p, 
(B) hsa-miR-210-3p, (C) hsa-miR-15a-5p, (D) hsa-miR-130a-3p, (E) hsa-miR-16-5p, (F) hsa-miR-342-3p, (G) hsa-miR-361-5p, (H) hsa-
miR-30a-3p, (I) hsa-miR-10b-5p and in (J) for hsa-miR-100-5p. The statistical significance was determined using unpaired student’s t-tests 
with two-tailed p-values ≤ 0.05 considered statistically significant. 
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210 expression is not a consequence of aberrant DNA 
methylation at any of the three tested regions. 
DISCUSSION
Lung cancer is responsible for the most cancer-
related deaths worldwide and the majority of these deaths 
are caused by metastatic disease. Identification of the 
molecular mechanisms leading to lung cancer metastasis 
may therefore hold the key to lowering the mortality of the 
disease. The non-coding RNA transcriptome is an area of 
increasing scientific interest and its critical role in human 
carcinogenesis is continuously being uncovered [38, 39]. 
This study is, to the best of our knowledge, the first to 
interrogate the entire miRNA transcriptome in relation to 
lung cancer metastasis by miRNA-seq and provides a full 
profile of all miRNAs that are expressed in metastasizing 
and non-metastasizing lung adenocarcinomas, as well as 
information regarding their relative abundance in these 
tissues. We compared the miRNA transcriptomes of the 
metastasizing and non-metastasizing LACs and while only 
subtle differences in miRNA expression were detected, we 
identified nine miRNAs that demonstrated a significant 
change in expression between the two groups: miR-101-3p, 
miR-210-3p, miR-15a-5p, miR-130a-3p, let-7e-5p, miR-
16-5p, miR-342-3p, miR-769-5p and miR-361-5p. 
Due to the size similarity between miRNA and 
piRNA, we also obtained full profiles of the piRNA 
transcriptomes in metastasizing and non-metastasizing 
lung adenocarcinomas, which provide important 
information concerning the role and abundance of 
piRNA in human malignancies. Eight piRNAs exhibited 
differential expression between the metastasizing and 
non-metastasizing LACs. The most pronounced difference 
was detected for piR-57125, which was significantly 
downregulated in the metastasizing LACs as compared to 
the non-metastasizing LACs (p = 0.0068). Interestingly, 
piR-57125 was also recently shown to be significantly 
downregulated in metastasizing compared to non-
metastasizing clear cell renal cell carcinomas [40]. These 
results strongly suggest that piR-57125 may function as 
a suppressor of cancer metastasis and it would therefore 
be highly interesting to functionally characterize this 
small RNA, as well as to investigate if this is a common 
observation in other metastasizing solid tumors. 
In the present study, 10 miRNAs demonstrating a 
significant or near-significant difference in expression 
between the metastasizing and non-metastasizing tumors 
were selected to undergo validation in our LAC cohorts 
by RT-qPCR. We were able to confirm a statistically 
significant difference in expression between metastasizing 
and non-metastasizing LACs for miR-30a-3p, miR-16-5p 
and miR-210-3p with similar or more pronounced 
changes in expression levels observed in the paired 
distant metastases. Both miR-30a-3p and miR-16-5p 
were significantly downregulated in the metastasizing 
Table 3: miR-210-3p expression vs. clinicopathological parameters
Characteristic
miR-210-3p expression
N Mean SEM P
Gender
Male 22 1.036 0.190
0.4908
Female 30 0.898 0.099
Age
< Average (61.7 years) 25 0.863 0.112
0.3594
> Average (61.7 years) 27 1.044 0.157
Smoking status
Current Smoker 34 0.970 0.137
0.5704
Previous Smoker 16 0.847 0.117
T-Stage (TNM)
T1 18 0.844 0.127
0.4486
T2–T4 33 1.003 0.137
N Stage (TNM)
N0 33 0.991 0.143
0.8503
N1–N2 17 0.950 0.107
M-Stage (TNM)
M0 26 0.608 0.066
0.0002
M1 26 1.306 0.158
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tumors, which suggest that they could function as tumor 
suppressors and inhibit metastasis in LAC. miR-210-3p 
exhibited the strongest association with the presence 
of distant metastases in LAC patients. We found that 
miR-210-3p was upregulated in both the metastasizing and 
non-metastasizing LACs as compared to tumor-adjacent 
normal lung, with its expression being significantly 
higher in the metastasizing than in the non-metastasizing 
LACs.  To further ensure the validity of our findings, we 
analyzed the publicly available LAC miRNA expression 
datasets in the TGCA database, which confirmed that miR-
210-3p and miR-30a-3p are indeed significantly up- and 
downregulated, respectively, in LAC compared to paired 
tumor-adjacent normal lung samples. While we did not 
detect a statistically significant association between the 
expression of miR-30a-3p, miR-16-5p and miR-210-3p 
and distant metastatic disease in the TCGA samples, we 
did find a borderline significant association between low 
miR-30a-3p expression levels and the presence of lymph 
node metastases and disease recurrence, which are traits 
of aggressive tumor behavior. We moreover found that 
the mean expression level of miR-210-3p was more than 
1.3 fold higher in the metastasizing vs. non-metastasizing 
LACs, and we therefore believe that the lack of significant 
association is most likely due to the rather small sample 
size of the TCGA M1 group (M1, n = 23 vs. M0 = 346). 
Figure 5: Increased expression of miR-210 is associated with distant metastasis in LAC. The association between 
miR-210-3p expression and distant metastasis in LAC was investigated. (A) The relative quantity (RQ) of miR-210-3p was determined 
by RT-qPCR and shown as a bar graph representing the mean expression in each group with error bars indicating the standard error of the 
mean (SEM). (B) The expression of miR-210-3p was investigated by microRNA in situ hybridization in 3 tumor-adjacent normal lung 
samples, 3 LACs without metastases, 3 LAC with distant metastases and 3 paired brain metastasis. A scrambled probe was included as a 
negative control. Representative images from each sample group are shown. (C) The RQ of miR-210-3p determined by RT-qPCR in the 
metastasizing (LAC w/ M) and non-metastasizing (LAC w/o M) LAC are shown as a dot plot for visualization of variation in expression 
within each group. Unpaired student’s t-tests were used to compare miR-210-3p expression between groups and two-tailed p-values ≤ 0.05 
considered statistically significant. (D) A Receiver Operating Characteristic (ROC) curve was used to determine the potential of miR-210-3p 
expression as a biomarker for distant metastasis in LAC. The Area Under the Curve (AUC) was calculated and the resulting p-value (Null 
hypothesis: AUC = 0.5) is indicated. 
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Combined, these results strongly indicate that upregulation 
of miR-210-3p and downregulation of miR-30a-3p 
play important roles in the development and metastatic 
progression of LAC. 
Downregulation of miR-30a is, in fact, a common 
observation in various malignancies, including lung 
cancer, and it has been shown to inhibit epithelial-to-
mesenchymal transition (EMT) and metastasis, as well as 
to be associated with poor prognosis in NSCLC [41–44]. 
miR-210 is a direct transcriptional target of HIF-1a and is 
induced in response to hypoxia [45]. Upregulation of miR-
210 is thus a frequent observation in cancer and increased 
Figure 6: Methylation assessment of the miR-210 promoter region. The methylation status of Region 1, 2 and 3 of the 
miR-210-3p promoter region was assessed in 26 metastasizing (LAC w/ M) and 26 non-metastasizing lung adenocarcinomas (LAC w/o M), 
as well as in 26 tumor-adjacent normal lung samples (NL) using MS-HRM analysis. “LAC” denotes the metastasizing and non-metastasizing 
LACs combined. A schematic representation of the genomic context of miR-210 is shown in (A) with the location of Region 1, 2 and 3 
within the CpG Island (CGI) indicated in black. The results of the methylation assessment are visualized as stacked bar percentage plots in 
(B) for Region 1, in (C) for Region 2 and in (D) for Region 3. In each category, the relative proportion of samples with 0-1% methylated 
templates are indicated in white, 1–10% methylated templates in white with light grey stripes, 10–50% methylated templates in dark 
grey and samples with 50–100% methylated templates are indicated in black.  For Region 1, normalized melting profiles for the DNA 
methylation standards and (E) 10 tumor-adjacent normal lung samples, (F) 10 non-metastasizing LACs and (G) 10 metastasizing LACs 
are shown in representative singlicates. The 100% methylated standard is indicated in red, 50% methylated standard in dark blue, 10% 
methylated standard in green, 1% methylated standard in purple, 0.1% methylated standard in light blue and the 0 % methylated standard in 
yellow. The statistical significance was assessed using a Mann-Whitney test of ranks with two-tailed p-values ≤ 0.05 considered significant. 
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expression has been identified as an independent negative 
prognostic factor in several cancers, including breast, 
head-and-neck, pancreas, and lung cancer [19, 20, 46–50]. 
In LAC, increased expression of miR-210 in primary 
tumors has been shown to be significantly associated with 
a high risk of relapse and increased serum levels have 
been found associated with the presence of regional lymph 
node metastases in NSCLC [50, 51]. Increased expression 
of miR-210 has also been linked to metastatic progression 
in colon, stomach and liver cancer, and elevated plasma 
levels has been identified as a potential biomarker 
for early detection of metastatic disease in melanoma 
and breast cancer [52–56]. This study is, to the best of 
our knowledge, the first to link increased expression of 
miR-210-3p to the development of distant metastases in 
LAC and it therefore adds valuable information to the 
increasing amount of evidence of miR-210s critical role 
in cancer development and metastatic progression. 
Patient specimens are routinely formalin-fixed 
and paraffin embedded (FFPE) in pathology laboratories 
across the world, but the fixation procedure induces 
extensive DNA and RNA degradation, which limits its use 
for downstream molecular analyses. However, the vast 
abundance of archived FFPE patient material renders it a 
valuable type of research material and it is therefore equally 
important to recognize its potential as its limitations. 
Previous studies have reported successful miRNA-seq of 
FFPE material and our study serves to confirm this notion. 
Despite the high level of RNA degradation observed in our 
samples, we still obtained valuable data that demonstrated 
a high level of concordance with results obtained by RT-
qPCR [33]. We therefore wish to highlight the potential of 
FFPE material to study genome-wide changes in miRNA 
expression by miRNA-seq.  
In conclusion, this study provides a full profile of 
the miRNA and piRNA transcriptome in metastasizing 
and non-metastasizing LAC, thus bringing novel insight 
to the role of ncRNA in the pathogenesis of lung cancer. 
We have shown that upregulation of miR-210-3p 
and downregulation of miR-30a-3p are significantly 
associated with the formation of distant metastases and 
these changes therefore represent attractive candidates 
for novel biomarkers of distant metastasis in LAC. It 
would be highly relevant to validate our findings in a large 
retrospective cohort study, as well as to investigate the 
predictive value of these miRNAs in prospective cohort 
studies.  Moreover, it would be interesting for future 
studies to investigate if these changes can be detected in 
non-invasive patient samples, such as blood, expectorates 
or bronchial washings, as this could potentially allow them 
to be applied as diagnostic biomarkers for detection of 
undiscovered micrometastases, as well as for monitoring 
metastases-related recurrence in surgically resected 
patients. Lastly, it would be relevant to functionally 
characterize these miRNAs in relation to cancer 
metastasis, as well as to determine their potential as targets 
for novel miRNA inhibition or replacement therapies for 
prevention of metastases formation in LAC. 
MATERIALS AND METHODS
Patient samples
Formalin-fixed paraffin embedded (FFPE) surgical 
resections from 52 lung adenocarcinoma (LAC) patients 
were retrieved from the archives at the Department of 
Pathology, Aarhus University Hospital. The patients were 
divided into two cohorts depending on the existence of 
distant metastatic disease at the time of diagnosis. The 
first cohort comprised primary lung adenocarcinomas 
from 26 patients without distant metastatic disease and a 
minimum of 5 years of recurrence-free survival following 
surgery. The second cohort comprised primary lung 
adenocarcinomas and paired distant metastases (20 brain 
and 4 adrenal gland) from 26 patients with distant 
metastatic disease. The cohorts were matched on histology, 
tumor size (T-stage), gender, age, smoking status and the 
relative proportion of tumor cells in the surgical resections. 
Tumor-adjacent normal lung tissue from 26 patients was 
included as controls. The Regional Ethical Committee (De 
Videnskabsetiske Komitéer Region Midtjylland, Permission 
No.: 1-10-72-20-14) approved this study and all data was 
analyzed anonymously in accordance with the approval.  
RNA and DNA extraction
From each FFPE sample, 1 × 7 µm and 5 × 10 µm 
sections were cut for RNA and DNA extraction, 
respectively. RNA was extracted using the miRNeasy 
FFPE kit (Qiagen, Hilden, Germany) and eluted in a 
final volume of 17 µL RNase-free water according to 
the manufacturer´s instructions. Potential genomic DNA 
contamination in the eluted RNA was removed by DNase 
treatment. DNA was extracted using the QIAamp DNA 
FFPE Tissue Kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s protocol. RNA and DNA concentrations 
including OD (A260/280) were assessed using the 
NanoDrop 1000 (Thermo Scientific, Waltham, MA, USA).
Small RNA library preparation and sequencing 
The RNA integrity in each sample was evaluated 
using the Agilent Bioanalyzer RNA 6000 Nano assay 
(Agilent Technologies, Santa Clara, CA, USA). Small 
RNA libraries were constructed using TruSeq Small 
RNA Sample Prep Kit (Illumina, San Diego, CA, USA) 
following the manufacturer´s instructions. From each 
sample, 500 ng RNA was ligated to 3′ and 5′ adapters and 
then subjected to reverse transcription to obtain cDNA. 
The cDNA was amplified for 12 PCR cycles using a 
common primer and a primer containing an index tag. The 
amplified libraries were subsequently gel purified. The 
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size and purity of the obtained libraries were validated 
using the Agilent Bioanalyzer High Sensitivity DNA assay 
(Agilent Technologies, Santa Clara, CA, USA) and the 
concentrations were confirmed using the KAPA Library 
Quantification Kit (KAPA Biosystems, Wilmington, 
MA, USA). The libraries were subsequently pooled and 
sequenced on an Illumina Hiseq2000 instrument by the 
Beijing Genomics Institute (BGI).
miRNA-Seq analysis
Raw sequencing reads were filtered with FASTX-
Toolkit to trim away low-quality reads and cutadapt to 
remove adaptor sequences. The clean reads were mapped 
to a list of datasets using Bowtie. First, reads were mapped 
to miRNAs from miRBase v21 allowing zero mismatches, 
disregarding non-templated A/U tailing on mature miRNAs. 
Non-miRNA-mapping reads were subsequently matched 
against other relevant small RNA datasets: piRNA, tRNA, 
snRNA, snoRNA and Y RNA allowing one mismatch. To 
assess degradation, the remaining unmatched reads were 
mapped to long RNA datasets: rRNA, other RNAs from 
Rfam and refSeq mRNA. The expressions of miRNAs 
and piRNAs were normalized as counts per million 
miRNA/piRNA reads (CPM). Only miRNAs/piRNAs 
expressed above 100 CPM were used for further analysis. 
Heatmaps were performed in R using the Bioconductor 
package ComplexHeatmap. All miRNA/piRNA with mean 
expressions above 100 CPM were visualized in ascending 
order by p-value between the groups “without metastases” 
and “with metastases”. Data was log2 transformed and 
rows were mean centered prior to visualization.
cDNA synthesis and RT-qPCR
cDNA synthesis and RT-qPCR were performed 
using the miRCURY LNATM Universal RT microRNA 
PCR system (Exiqon, Vedbaek, Denmark) according to 
the manufacturer’s instructions. The cDNA synthesis was 
performed in duplicates for each sample with 10 ng RNA 
as input. The RT-qPCR was conducted on a LightCycler® 
480 (Roche, Mannheim, Germany) in a final volume 
of 5 µL comprising 2 × ExiLENT SYBR® master mix, 
cDNA and LNA™ PCR primers for hsa-miR-101-3p, 
hsa-miR-210-3p, hsa-miR-15a-5p, hsa-miR-130a-3p, 
hsa-miR-16-5p, hsa-miR-342-3p, hsa-miR-361-5p, hsa-
miR-30a-3p, hsa-miR-10b-5p, hsa-miR-100-5p and two 
miRNA reference genes, hsa-miR-103a-3p and hsa-miR-
423-5p [57, 58]. All expression data was analyzed using 
NormFinder to ensure the stability of the reference genes 
[59]. ΔCt values were calculated by normalizing to the 
geometric mean of the reference genes. Relative quantities 
(RQ) were calculated as 2–ΔCt and the RQ of the miRNAs 
of interest in each sample was determined as the mean RQ 
in the cDNA synthesis duplicates.
miRNA expression analysis using the cancer 
genome atlas (TCGA) database
Clinical information and miRNA expression data for 
hsa-miR-101-1 (3p), hsa-miR-101-2 (3p), hsa-miR-210-3p, 
hsa-miR-15a-5p, hsa-miR-130a-3p, hsa-miR-16-1 (5p), 
hsa-miR-16-2 (5p), hsa-miR-342-3p, hsa-miR-30a-3p, 
hsa-miR-10b-5p were retrieved from https://gdc-portal.nci.
nih.gov/ for more than 400 lung adenocarcinoma patients. 
miR in situ hybridization
miR-210-3p expression was analyzed by in situ 
hybridization using a 5′- and 3′-double digoxigenin-
labeled miRCURY LNATM microRNA Detection Probe 
(Exiqon, Vedbaek, Denmark) with minor modifications 
to the manufacturer’s protocol. U6 and a scrambled 
probe were included as positive and negative controls, 
respectively. In brief, the deparaffinized and proteinase 
K-digested sections were dehydrated and hybridized with 
40 nM double-DIG LNATM hsa-miR-210-3p probe for 
60 min at 54°C. Following a series of stringent saline-
sodium citrate buffer washes and blocking, the sections 
were incubated with a 1:125 dilution of anti-DIG Fab 
fragments conjugated to alkaline phosphatase (Roche 
Diagnostics, Mannheim, Germany). The anti-DIG/AP 
was replaced with fresh reagent after 30 min and the 
incubation was continued for an additional 30 min. For 
signal detection, the sections were incubated with freshly 
prepared NBT/BCIP AP substrate (Roche Diagnostics, 
Mannheim, Germany) at 30°C. After 60 min, fresh AP 
substrate was added and the incubation was continued for 
60 min. Lastly, Nuclear Fast RedTM (Vector laboratories, 
Burlingame, CA, USA) was used as a counterstain for 
visualization of the nuclei.    
Sodium bisulfite modification and methylation-
sensitive high resolution melting (MS-HRM) 
analysis
From each sample, 500 ng genomic DNA was 
subjected to sodium bisulfite modification using the EZ 
DNA Methylation-Gold™ Kit (Zymo Research, Irvine, 
CA, USA) and eluted in a final volume of 110 µl H2O 
according to the manufacturer’s instructions. Methylation 
assessment of Region 1, 2 and 3 of the miR-210 promoter 
was performed by MS-HRM analysis and the primers were 
designed to amplify both methylated and unmethylated 
DNA [60–62]. PCR and HRM were carried out on a 
LightCycler® 480 (Roche, Mannheim, Germany) with each 
10 µl reaction comprising 2 × MeltDoctorTM HRM Master 
Mix (Life Technologies, Carlsbad, CA, USA), 3 mM MgCl2, 
approximately 10 ng bisulfite modified DNA and 500 nM 
of each primer. The methylation assessment of each region 
was performed by melting profile comparison between each 
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sample and DNA methylation standards derived through 
a serial dilution of 100% methylated DNA (Universal 
Methylated Human DNA Standard, Zymo Research, Irvine, 
CA USA) into 0% methylated DNA (EpiTect Control DNA, 
Qiagen, Hilden, Germany). All analyses were done in 
triplicates and the technical specifications for the Region 
1, 2 and 3 MS-HRM assays, including primer sequences, 
genomic location, assay-specific PCR cycling and HRM 
protocols are listed in Supplementary Methods.  
Statistical analysis
The miRNA expression values determined by 
miRNA-seq and RT-qPCR were compared between groups 
using unpaired Student’s t-tests. The level of agreement 
between miRNA-seq and RT-qPCR was determined 
through linear regression and correlation analysis of the 
log2(normalized expression) values obtained by RT-qPCR 
plotted against the log2(normalized expression) values 
obtained by miRNA-seq. To obtain the log2(normalized 
expression) values, the expression value for each miRNA 
was normalized to the mean miRNA expression in all 
24 samples used for miRNA-seq and the values were then 
log2 transformed. Receiver Operating Characteristic curve 
analysis was used to determine the biomarker potential of 
miR-210-3p expression. miRNA expression data obtained 
from the TCGA database was compared between samples 
with and without distant metastases, with and without lymph 
node metastases and samples from patients with and without 
recurrent disease using a Mann-Whitney test of ranks, and 
between paired tumor-adjacent normal lung and tumor tissue 
samples using a Wilcoxon matched pairs signed rank test. 
The methylation frequencies of Region 1, 2 and 3 were 
compared between groups using a Mann-Whitney test of 
ranks. Samples were ranked according to their determined 
level of methylation with samples demonstrating 0–1% 
methylation ranked 1, 1–10% methylation ranked 2, 10–50% 
methylation ranked 3 and 50–100% methylation ranked 4. 
All analyses were conducted using GraphPad Prism version 
6 software (GraphPad Software, La Jolla, CA, USA) with 
two-tailed p-values ≤ 0.05 considered statistically significant.
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